Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02246621




Registration number
NCT02246621
Ethics application status
Date submitted
18/09/2014
Date registered
23/09/2014
Date last updated
8/10/2024

Titles & IDs
Public title
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting
Secondary ID [1] 0 0
I3Y-MC-JPBM
Secondary ID [2] 0 0
15417
Universal Trial Number (UTN)
Trial acronym
MONARCH 3
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Abemaciclib
Treatment: Drugs - Anastrozole
Treatment: Drugs - Letrozole
Treatment: Drugs - Placebo

Experimental: Abemaciclib + NSAI - 150 milligrams (mg) Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).

Placebo comparator: Placebo + NSAI - Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).


Treatment: Drugs: Abemaciclib
Administered orally

Treatment: Drugs: Anastrozole
Administered orally

Treatment: Drugs: Letrozole
Administered orally

Treatment: Drugs: Placebo
Administered orally
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS)
Timepoint [1] 0 0
Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Randomization to Progressive Disease or Death Due to Any Cause (Estimated Up to 82 Months)
Secondary outcome [2] 0 0
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
Timepoint [2] 0 0
Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
Secondary outcome [3] 0 0
Duration of Response (DoR)
Timepoint [3] 0 0
CR or PR to Disease Progression or Death Due to Any Cause (Up to 32 Months)
Secondary outcome [4] 0 0
Percentage of Participants With CR, PR or Stable Disease (SD) (Disease Control Rate [DCR])
Timepoint [4] 0 0
Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
Secondary outcome [5] 0 0
Percentage of Participants With Tumor Response of SD for at Least 6 Months, PR, or CR (Clinical Benefit Rate [CBR])
Timepoint [5] 0 0
Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
Secondary outcome [6] 0 0
Change From Baseline to End of Study in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Functional Scale Scores
Timepoint [6] 0 0
Baseline, End of Study (Up to 32 Months)
Secondary outcome [7] 0 0
Change From Baseline to End of Study in Symptom Burden on the EORTC QLQ-C30 Symptom Scale Scores
Timepoint [7] 0 0
Baseline, End of Study (Up to 32 Months)
Secondary outcome [8] 0 0
Change From Baseline to End of Study in Symptom Burden on the EORTC QLQ-Breast23 Questionnaire
Timepoint [8] 0 0
Baseline, End of Study (Up to 32 Months)
Secondary outcome [9] 0 0
Change From Baseline to End of Study in Health Status on the EuroQuol 5-Dimension 5 Level (EuroQol-5D 5L) Index Value
Timepoint [9] 0 0
Baseline, End of Study (Up to 32 Months)
Secondary outcome [10] 0 0
Change From Baseline to End of Study in Health Status on the EuroQol-5D 5L Visual Analog Scale (VAS) Scores Scale
Timepoint [10] 0 0
Baseline, End of Study (Up to 32 Months)
Secondary outcome [11] 0 0
Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-8)] of Abemaciclib and Its Metabolites M2 and M20
Timepoint [11] 0 0
Cycle 1 Day 1; 2 to 4 hours (h) post dose, Cycle 2 Day 1; 3 h post dose; 7 h post dose, Cycle 3 Day 1; pre dose, 3 h post dose
Secondary outcome [12] 0 0
PK: Hepatic Clearance of Abemaciclib, and Apparent Hepatic Clearance of Its Metabolites M2 and M20
Timepoint [12] 0 0
Cycle 1 Day 1; 2 to 4 hours (h) post dose, Cycle 2 Day 1; 3 h post dose; 7 h post dose, Cycle 3 Day 1; pre dose, 3 h post dose

Eligibility
Key inclusion criteria
* Have a diagnosis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer
* Have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease
* Have postmenopausal status
* Have either measurable disease or nonmeasurable bone-only disease
* Have a performance status =1 on the Eastern Cooperative Oncology Group (ECOG) scale
* Have adequate organ function
* Have discontinued previous localized radiotherapy for palliative purposes or for lytic lesions at risk of fracture prior to randomization and recovered from the acute effects of therapy
* Are able to swallow capsules
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
* Have inflammatory breast cancer
* Have clinical evidence or a history of central nervous system (CNS) metastasis
* Are currently receiving or have previously received endocrine therapy for locoregionally recurrent or metastatic breast cancer
* Have received prior (neo)adjuvant endocrine therapy with a disease-free interval =12 months from completion of treatment
* Are currently receiving or have previously received chemotherapy for locoregionally recurrent or metastatic breast cancer
* Have received prior treatment with everolimus
* Have received prior treatment with any cyclin-dependent kinase (CDK) 4/6 inhibitor (or participated in any CDK4/6 inhibitor clinical trial for which treatment assignment is still blinded)
* Have initiated bisphosphonates or approved receptor activator of nuclear factor kappa-B ligand (RANK-L) targeted agents <7 days prior to randomization
* Are currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study
* Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of randomization for a nonmyelosuppressive or myelosuppressive agent, respectively
* Have had major surgery within 14 days prior to randomization

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/11/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2025
Actual
Sample size
Target
Accrual to date
Final
493
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Chris O'Brien Lifehouse - Camperdown
Recruitment hospital [2] 0 0
St Vincent's Hospital - Sydney
Recruitment hospital [3] 0 0
Sydney Adventist Hospital - Wahroonga
Recruitment hospital [4] 0 0
Mater Adult Hospital Brisbane - South Brisbane
Recruitment hospital [5] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [6] 0 0
The Queen Elizabeth Hospital - Woodville
Recruitment hospital [7] 0 0
Barwon Health - The Geelong Hospital - Geelong
Recruitment hospital [8] 0 0
St. John of God Murdoch Hospital - Murdoch
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2010 - Sydney
Recruitment postcode(s) [3] 0 0
2076 - Wahroonga
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [6] 0 0
5011 - Woodville
Recruitment postcode(s) [7] 0 0
3220 - Geelong
Recruitment postcode(s) [8] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Minnesota
Country [7] 0 0
United States of America
State/province [7] 0 0
Nebraska
Country [8] 0 0
United States of America
State/province [8] 0 0
Nevada
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
Austria
State/province [12] 0 0
Oberösterreich
Country [13] 0 0
Austria
State/province [13] 0 0
Steiermark
Country [14] 0 0
Austria
State/province [14] 0 0
Tirol
Country [15] 0 0
Austria
State/province [15] 0 0
Wien
Country [16] 0 0
Belgium
State/province [16] 0 0
Antwerpen
Country [17] 0 0
Belgium
State/province [17] 0 0
Brussel
Country [18] 0 0
Belgium
State/province [18] 0 0
Bruxelles-Capitale, Région De
Country [19] 0 0
Belgium
State/province [19] 0 0
Charleroi
Country [20] 0 0
Belgium
State/province [20] 0 0
Namur
Country [21] 0 0
Belgium
State/province [21] 0 0
Roeselare
Country [22] 0 0
Canada
State/province [22] 0 0
Alberta
Country [23] 0 0
Canada
State/province [23] 0 0
Ontario
Country [24] 0 0
Canada
State/province [24] 0 0
Quebec
Country [25] 0 0
France
State/province [25] 0 0
Aquitaine
Country [26] 0 0
France
State/province [26] 0 0
Bretagne
Country [27] 0 0
France
State/province [27] 0 0
Côte-d'Or
Country [28] 0 0
France
State/province [28] 0 0
Côtes-d'Armor
Country [29] 0 0
France
State/province [29] 0 0
Languedoc-Roussillon
Country [30] 0 0
France
State/province [30] 0 0
Loire-Atlantique
Country [31] 0 0
France
State/province [31] 0 0
Meurthe-et-Moselle
Country [32] 0 0
France
State/province [32] 0 0
Rhône-Alpes
Country [33] 0 0
France
State/province [33] 0 0
Vendée
Country [34] 0 0
France
State/province [34] 0 0
Besancon Cedex
Country [35] 0 0
Germany
State/province [35] 0 0
Baden-Württemberg
Country [36] 0 0
Germany
State/province [36] 0 0
Bayern
Country [37] 0 0
Germany
State/province [37] 0 0
Hessen
Country [38] 0 0
Germany
State/province [38] 0 0
Nordrhein-Westfalen
Country [39] 0 0
Germany
State/province [39] 0 0
Schleswig-Holstein
Country [40] 0 0
Germany
State/province [40] 0 0
Hamburg
Country [41] 0 0
Greece
State/province [41] 0 0
Attikí
Country [42] 0 0
Israel
State/province [42] 0 0
HaMerkaz
Country [43] 0 0
Israel
State/province [43] 0 0
Yerushalayim
Country [44] 0 0
Israel
State/province [44] 0 0
Beer Sheva
Country [45] 0 0
Israel
State/province [45] 0 0
Kfar Saba
Country [46] 0 0
Israel
State/province [46] 0 0
Tel Aviv
Country [47] 0 0
Israel
State/province [47] 0 0
?eifa
Country [48] 0 0
Italy
State/province [48] 0 0
BR
Country [49] 0 0
Italy
State/province [49] 0 0
Ferrara
Country [50] 0 0
Italy
State/province [50] 0 0
Liguria
Country [51] 0 0
Italy
State/province [51] 0 0
Torino
Country [52] 0 0
Italy
State/province [52] 0 0
Toscana
Country [53] 0 0
Italy
State/province [53] 0 0
Verona
Country [54] 0 0
Italy
State/province [54] 0 0
Bergamo
Country [55] 0 0
Italy
State/province [55] 0 0
Bologna
Country [56] 0 0
Italy
State/province [56] 0 0
Messina
Country [57] 0 0
Italy
State/province [57] 0 0
Roma
Country [58] 0 0
Italy
State/province [58] 0 0
Terni
Country [59] 0 0
Japan
State/province [59] 0 0
Aichi
Country [60] 0 0
Japan
State/province [60] 0 0
Chiba
Country [61] 0 0
Japan
State/province [61] 0 0
Ehime
Country [62] 0 0
Japan
State/province [62] 0 0
Hokkaido
Country [63] 0 0
Japan
State/province [63] 0 0
Hyogo
Country [64] 0 0
Japan
State/province [64] 0 0
Kanagawa
Country [65] 0 0
Japan
State/province [65] 0 0
Niigata
Country [66] 0 0
Japan
State/province [66] 0 0
Osaka
Country [67] 0 0
Japan
State/province [67] 0 0
Saitama
Country [68] 0 0
Japan
State/province [68] 0 0
Shizuoka
Country [69] 0 0
Japan
State/province [69] 0 0
Tochigi
Country [70] 0 0
Japan
State/province [70] 0 0
Tokyo
Country [71] 0 0
Japan
State/province [71] 0 0
Fukuoka
Country [72] 0 0
Japan
State/province [72] 0 0
Hiroshima
Country [73] 0 0
Japan
State/province [73] 0 0
Kyoto
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Incheon-gwangyeoksi [Incheon]
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Kyonggi-do
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Seoul-teukbyeolsi [Seoul]
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Taegu-Kwangyokshi
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Ulsan-Kwangyokshi
Country [79] 0 0
Mexico
State/province [79] 0 0
Coahuila
Country [80] 0 0
Mexico
State/province [80] 0 0
Distrito Federal
Country [81] 0 0
Mexico
State/province [81] 0 0
Federal District
Country [82] 0 0
Mexico
State/province [82] 0 0
Guanajuato
Country [83] 0 0
Mexico
State/province [83] 0 0
Jalisco
Country [84] 0 0
Mexico
State/province [84] 0 0
Morelos
Country [85] 0 0
Mexico
State/province [85] 0 0
Oaxaca
Country [86] 0 0
Mexico
State/province [86] 0 0
Queretaro
Country [87] 0 0
Netherlands
State/province [87] 0 0
Zuid-Holland
Country [88] 0 0
Netherlands
State/province [88] 0 0
Leiden
Country [89] 0 0
New Zealand
State/province [89] 0 0
Auckland
Country [90] 0 0
Russian Federation
State/province [90] 0 0
Arkhangel'skaya Oblast'
Country [91] 0 0
Russian Federation
State/province [91] 0 0
Moskva
Country [92] 0 0
Russian Federation
State/province [92] 0 0
Russia
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Moscow
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Saint-Petersburg
Country [95] 0 0
Russian Federation
State/province [95] 0 0
St. Petersburg
Country [96] 0 0
Slovakia
State/province [96] 0 0
Bratislavský Kraj
Country [97] 0 0
Slovakia
State/province [97] 0 0
Košický Kraj
Country [98] 0 0
Spain
State/province [98] 0 0
Badajoz
Country [99] 0 0
Spain
State/province [99] 0 0
Barcelona
Country [100] 0 0
Spain
State/province [100] 0 0
Lleida
Country [101] 0 0
Spain
State/province [101] 0 0
Madrid
Country [102] 0 0
Spain
State/province [102] 0 0
San Sebastian
Country [103] 0 0
Spain
State/province [103] 0 0
Valencia
Country [104] 0 0
Sweden
State/province [104] 0 0
Gavle
Country [105] 0 0
Sweden
State/province [105] 0 0
Orebro
Country [106] 0 0
Sweden
State/province [106] 0 0
Vasteras
Country [107] 0 0
Taiwan
State/province [107] 0 0
Jhonghe City
Country [108] 0 0
Taiwan
State/province [108] 0 0
Kuei Shan Hsiang
Country [109] 0 0
Taiwan
State/province [109] 0 0
Pei-Tou
Country [110] 0 0
Taiwan
State/province [110] 0 0
Taichung
Country [111] 0 0
Taiwan
State/province [111] 0 0
Taipei
Country [112] 0 0
Turkey
State/province [112] 0 0
Ankara
Country [113] 0 0
Turkey
State/province [113] 0 0
Edirne
Country [114] 0 0
Turkey
State/province [114] 0 0
Malatya
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Bebbington
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Cambridge
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Manchester
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women with breast cancer. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio.
Trial website
https://clinicaltrials.gov/study/NCT02246621
Trial related presentations / publications
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tredan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.
Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019 Jan 17;5:5. doi: 10.1038/s41523-018-0097-z. eCollection 2019.
Takahashi M, Tokunaga E, Mori J, Tanizawa Y, van der Walt JS, Kawaguchi T, Goetz MP, Toi M. Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Breast Cancer. 2022 Jan;29(1):174-184. doi: 10.1007/s12282-021-01295-0. Epub 2021 Oct 18.
Goetz MP, Okera M, Wildiers H, Campone M, Grischke EM, Manso L, Andre VAM, Chouaki N, San Antonio B, Toi M, Sledge GW Jr. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Res Treat. 2021 Apr;186(2):417-428. doi: 10.1007/s10549-020-06029-y. Epub 2021 Jan 3.
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02246621